Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 570 | 501 | 424 | 477 | 931 |
| Gross Profit | 570 | 501 | 424 | 477 | 931 |
| Operating Expenses | 30,319 | 44,138 | 29,682 | 34,772 | 39,842 |
| Operating Income | -29,749 | -43,637 | -29,258 | -34,295 | -38,911 |
| Interest Expense | 0 | 0 | 0 | 0 | 5,610 |
| Other Income | 3,017 | 3,834 | 1,386 | 363 | -135 |
| Pre-tax Income | -26,732 | -39,803 | -27,872 | -33,932 | -44,656 |
| Income Tax | 4 | 4 | N/A | 13 | -448 |
| Net Income Continuous | -26,736 | -39,807 | -27,872 | -33,945 | -44,208 |
| Net Income Discontinuous | 253 | -27 | -580 | 10,735 | -29,121 |
| Net Income | $-26,483 | $-39,834 | $-28,452 | $-23,210 | $-73,329 |
| EPS Basic Total Ops | -0.62 | -0.93 | -2.78 | -7.28 | -25.64 |
| EPS Basic Continuous Ops | -0.63 | -0.93 | -2.72 | -10.65 | -15.46 |
| EPS Basic Discontinuous Ops | 0.01 | 0.00 | -0.06 | 3.37 | -10.18 |
| EPS Diluted Total Ops | -0.62 | -0.93 | -2.78 | -7.28 | -25.64 |
| EPS Diluted Continuous Ops | -0.63 | -0.93 | -2.72 | -10.65 | -15.46 |
| EPS Diluted Discontinuous Ops | 0.01 | 0.00 | -0.06 | 3.37 | -10.18 |
| EPS Diluted Before Non-Recurring Items | -0.62 | -0.93 | -2.72 | -10.65 | -25.54 |
| EBITDA(a) | $-30,504 | $-46,076 | $-29,513 | $-34,223 | $-38,802 |